Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease
Friday, April 05, 2024Acumen Pharmaceuticals a clinicalstage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimers disease
Merck Begins Phase 3 Trial of MK-1084, Oral KRAS G12C Inhibitor, with KEYTRUDA® for Lung Cancer
Friday, April 05, 2024Merck known as MSD outside of the United States and Canada today announced it has initiated a Phase clinical trial evaluating MK an investigational oral selective KRAS GC inhibitor in combination
ProMed Pharma Acquires SpineThera Manufacturing Capabilities and an Option to License Intellectual Property
Thursday, April 04, 2024SpineThera Inc a privately held clinicalstage pharmaceutical company focused on the development of SX and ProMed Pharma LLC a leading contract manufacturer of polymerbased drug releasing dosage
Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement
Thursday, April 04, 2024Kintara Therapeutics Inc a biopharmaceutical company investigating REM in an NIHsponsored and funded open label study in cutaneous metastatic breast cancer and TuHURA Biosciences Inc a Phase registrationstage
Ipsen and Sutro Biopharma Announce Exclusive Global Licensing Agreement for an ADC Targeting Solid Tumors
Wednesday, April 03, 2024Ipsen and Sutro Biopharma today announced an exclusive global licensing agreement for STRO STRO an antibodydrug conjugate in the final stages of preclinical development targets the ROR
VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform
Wednesday, April 03, 2024VBI Vaccines Inc a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease today announced
European Commission Approves Bristol Myers Squibb’s Reblozyl® for First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk MDS
Wednesday, April 03, 2024Bristol Myers Squibb today announced that the European Commission has expanded approval of Reblozyl to include the firstline treatment of adult patients
2seventy Bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron
Tuesday, April 02, 2024seventy bio Inc announced today the completion of the asset purchase agreement by Regeneron Pharmaceuticals Inc Under the terms of the APA Regeneron has acquired all oncology and autoimmune research and development
Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
Monday, April 01, 2024Vertex Pharmaceuticals Incorporated today announced that inaxaplin has advanced into the Phase portion of the global Phase pivotal clinical trial
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
Saturday, March 30, 2024Mustang Bio Inc a clinicalstage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for difficulttotreat cancers
